Evidence map›Paper›PMID 31218455›Full record

ReviewCurrent oncology reports2019

Cerebral Radiation Necrosis: Incidence, Pathogenesis, Diagnostic Challenges, and Future Opportunities.

Faisal S Ali, Octavio Arevalo, Soheil Zorofchian, Anthony Patrizz, Roy Riascos, Nitin Tandon, Angel Blanco, Leomar Y Ballester, Yoshua Esquenazi

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05861245 (Phase II Clinical Trial of Low-intervention Using Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base), which is not on this map. Cited by 93 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 6 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05861245 narecruitingnot on this mapstarted 2023, after this paper: background citation

Phase II Clinical Trial of Low-intervention Using Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base

TypeinterventionalSponsorQuironsaludRan2023 to 2033Enrolled20ConditionsChordoma, ChondrosarcomaArms5-fraction hipofractionated protontheray, 25-fraction hypofractionated proton therapy
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 6 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. A Mechanistic Model of Brain Necrosis Progression Based on Vascular Heterogeneity.International journal of radiation oncology, biology, physics · 2026
    Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Faisal S AliDepartment of Internal Medicine, Saint Joseph Hospital, Chicago, IL, USA.
Octavio ArevaloDepartment of Neuroradiology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Soheil ZorofchianVivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center, McGovern Medical School, Houston, TX, 77030, USA.
Anthony PatrizzVivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center, McGovern Medical School, Houston, TX, 77030, USA.
Roy RiascosDepartment of Neuroradiology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Nitin TandonVivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center, McGovern Medical School, Houston, TX, 77030, USA.
Angel BlancoVivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center, McGovern Medical School, Houston, TX, 77030, USA.
Leomar Y BallesterDepartment of Pathology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, 77030, USA. leomar.y.ballester@uth.tmc.edu.
Yoshua EsquenaziVivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center, McGovern Medical School, Houston, TX, 77030, USA. yoshua.esquenazilevy@uth.tmc.edu.
The University of Texas Health Science Center at Houston · USSaint Joseph Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewCerebral radiation necrosis (CRN) is a major dose-limiting adverse event of radiotherapy. The incidence rate of RN varies with the radiotherapy modality, total dose, dose fractionation, and the nature of the lesion being targeted. In addition to these known and controllable features, there is a stochastic component to the occurrence of CRN-the genetic profile of the host or the lesion and their role in the development of CRN. RECENT

findingsRecent studies provide some insight into the genetic mechanisms underlying radiation-induced brain injury. In addition to these incompletely understood host factors, the diagnostic criteria for CRN using structural and functional imaging are also not clear, though multiple structural and functional imaging modalities exist, a combination of which may prove to be the ideal diagnostic imaging approach. As the utilization of novel molecular therapies and immunotherapy increases, the incidence of CNR is expected to increase and its diagnosis will become more challenging. Tissue biopsies can be insensitive and suffer from sampling biases and procedural risks. Liquid biopsies represent a promising, accurate, and non-invasive diagnostic strategy, though this modality is currently in its infancy. A better understanding of the pathogenesis of CRN will expand and optimize the diagnosis and management of CRN by better utilizing existing treatment options including bevacizumab, pentoxifylline, hyperbaric oxygen therapy, and laser interstitial thermal therapy.

Indexed as

BevacizumabBrainBrain NeoplasmsDiagnosis, DifferentialHumansIncidenceLaser TherapyLiquid BiopsyMagnetic Resonance ImagingNecrosisRadiation InjuriesRisk FactorsBevacizumabBevacizumabBiomarkersBrain tumorsGliomasImagingLaser interstitial thermal therapyPseudo-progressionRadiation necrosisRadiotherapyStereotactic radiosurgeryTumor progression

Identifiers

PMID31218455
OpenAlexW2952717871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.